Prospective F-18 FDOPA PET Imaging Study in Human PD.

Area of Science:

• Neurology
• Radiology
• Nuclear Medicine

Background:

• Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons.
• Accurate and early diagnosis of PD is crucial for effective management and treatment.
• Positron emission tomography (PET) imaging offers a potential method for visualizing dopaminergic pathways.

Purpose of the Study:

• To evaluate the diagnostic performance of 3,4-dihydroxy-6-[18F]fluoro-l-phenylalanine (F-18 FDOPA) PET imaging in patients with parkinsonian syndromes.
• To determine the sensitivity, specificity, and predictive values of F-18 FDOPA PET compared to a clinical standard-of-truth (SOT).
• To assess inter-rater reliability and the correlation of quantitative PET measures with dopaminergic status.

Main Methods:

• A prospective study involving 68 subjects with parkinsonian symptoms.
• F-18 FDOPA PET scans were acquired 80-100 minutes post-injection, alongside CT scans.
• Image interpretation was performed by an expert and two experienced physicians, blinded to clinical data and SOT.

Main Results:

• Out of 56 subjects with determined SOT, 47 showed agreement between F-18 FDOPA PET results and SOT.
• The specificity and positive predictive value of F-18 FDOPA PET were 91% and 92%, respectively.
• The sensitivity was 73%, with inter-rater agreement ranging from 0.6 to 0.8.

Conclusions:

• F-18 FDOPA PET imaging demonstrates high specificity and moderate sensitivity for diagnosing Parkinson's disease.
• The study findings supported the FDA New Drug Application approval for F-18 FDOPA PET in PD diagnosis.
• This imaging modality is a valuable tool for assessing dopaminergic degeneration in patients with suspected PD.